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Summary 
Pertussis toxin plays a major role in the pathogenesis of whooping cough and is considered an 
important constituent of vaccines against this disease. It is composed of five different subunits 
associated in a molar ratio  1S1:1S2:1S3:2S4:1S5. The $1 subunit is responsible  for the ADP- 
ribosyltransferase  activity of the toxin. The B moiety, composed of $2 through $5, recognizes 
and binds to the target cell receptors and has some ADP-ribosyltransferase-independent activities 
such as mitogenicity. Site-directed mutagenesis of subunits $2 and $3 allowed us to identify amino 
acid residues involved in receptor binding. Of all the modifications generated, the deletion of 
Ash 105 in $2 and of Lys 105 in $3 resulted in the more drastic reduction of binding to haptogiobin 
and CHO cells, respectively. A holotoxin carrying both deletions presented a mitogenicity reduced 
to an undetectable level. The combination of these B oligomer mutations with two substitutions 
in the $1 subunit led to the production of a toxin analog with reduced ADPoribosyltransferase- 
dependent and -independent activities including mitogenicity. As shown by immunoprecipitation 
with various monodonal antibodies, the mutant holotoxin was correctly assembled and antigenically 
similar to the native toxin. This toxin analog induced toxin-neutralizing antibodies at the same 
level as the holotoxin carrying only mutations in the $1 subunit, and may therefore be considered 
a useful candidate for the development of a new generation vaccine against whooping cough. 
tel/a pertuss/s, the etiologic agent of whooping cough, 
duces a number of toxins responsible for the local 
and systemic manifestations of this important childhood dis- 
ease (1). Among these toxins, pertussis toxin (PTX) 1 plays 
a major role in the pathogenesis, in that it expresses a wide 
variety of biological activities,  such as histamine sensitiza- 
tion, activation of insulin secretion, promotion of lymphocy- 
toffs, and others (2). In addition, immunization with PTX 
has been shown to protect mice against subsequent lethal chal- 
lenge with virulent R pertuss/s (3). It is therefore considered 
an important constituent in vaccines against pertussis,  and 
is the major component of the new acellnlar vaccines cur- 
rently being tested or used in several countries (4,  5). 
Paradoxically, this toxin may itself be responsible  for the 
harmful side effects associated with the current vaccines (6). 
These side effects range in severity from minor local reac- 
tions and simple flushing, to permanent neurological damage 
t Abbre~aons used in this paper: CRAM, cross-reactive mutant; NAD, 
nicotinamide  adenine dinudeotide; FTX, txn'tussis toxin; WT, wild type. 
and, in some rare cases, death. Before PTX can effectively 
and safely be used in pertussis vaccines, complete and irre- 
versible detoxification is therefore required. 
The toxin is composed of five different subunits, named 
$1 to $5, based on their decreasing molecular weights. The 
subunits associate in a molar ratio of 1S1:1S2:1S3:2S4:1S5 to 
form the holotoxin. Functionally, FTX can be divided into 
the A protomer, or $1 subunit, capable of expressing enzy- 
matic ADP-ribosyltransferase  activity,  and  the B  moiety, 
responsible for the target cell receptor binding activities (7). 
The B oligomer is in turn composed of two dimers, D1 and 
D2, connected by subunit $5. Dimer D1 comprises subunits 
$2 and $4,  and dimer D2 subunits $3 and $4 (7). 
As for many bacterial protein toxins with an A-B struc- 
ture, toxicity of PTX relies on three molecular steps. First, 
the toxin binds via its B moiety to the target cell receptors. 
Then,  the  enzymatically active  A  moiety is  translocated 
through the target cell membrane. Finally, the A protomer 
expresses its ADP-ribosyltransferase  activity using NAD as 
the ADP-ribose donor. Elimination of any of these steps should 
drastically  reduce the biological activities  of PTX. Akera- 
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in the active site of the $1 subunit (8-11) have indeed yielded 
PTX-cross-reactive mutant proteins (PTX-CRM) drastically 
affected in many of the biological activities (12-14).  How- 
ever, some biological activities are independent of the ADP- 
ribosyltransferase activity (15). Of concern is PTX-assodated 
mitogenicity, one of the activities that are not reduced by 
inactivation of the $1 subunit (16). Since it is unclear which 
precise molecular activities especially cause the rare but se- 
vere side effects of current pertussis vaccines,  it is desirable 
to abolish  all measurable biological activities of the PTX- 
CRM molecules used in the future vaccines. 
Whereas abolition of the ADP-ribosyltransferase activity, 
the last of the three molecular steps in cytotoxidty, only affects 
some toxin activities, reduction of all biological activities can 
be expected if the initial, B oligomer-mediated binding step 
of the toxin to the target cell receptors is abolished. 
Although the receptors of PTX have not been identified 
yet, several studies have indicated that they are glycoproteins 
of variable sizes depending on the target cell (17-19).  Wit- 
vliet et al. (18) showed that a 165-kD protein on the surface 
of CHO cells was preferentially recognized by dimer 2 ($3- 
$4),  but  not  by  dimer  1  ($2-$4).  On  the  other  hand, 
sialoglycoproteins haptoglobin and fetuin have been used as 
model systems for the interaction of PTX with at least one 
class of receptors. It has been shown, using an enzyme-linked 
immunosorbent assay, that dimer 1 but not dimer 2 is able 
to bind to haptoglobin (20, 21). Even the $2 subunit alone 
was able to bind to haptoglobin, albeit less efficiently than 
the $2-$4 dimer (21). Taken together, these results suggest 
that the receptor-binding sites of PTX are likely to involve 
subunits $2 and $3. The high degree of sequence similarity 
of these two subunits (22, 23) further suggests that the binding 
sites share some common features. On the other hand, since 
there appears to be some specificity in the interaction of the 
individual dimers to their respective receptors (18, 21), receptor 
binding activities most likely also involve some of the non- 
conserved residues. 
In this communication, we describe the identification of 
amino acid residues involved in B oligomer activities,  their 
site-directed modification, and the construction of an immuno- 
genic vaccine candidate PTX-CRM devoid of cytotoxic and 
mitogenic activities. 
Materiah and Methods 
Strains, Plasmids, and Culture Medium.  R pertussis BPRA, from 
which the ptx operon has been deleted, and plasmid pRIT13070, 
containing the entire ptx operon inserted into the EcoRI site of 
pUC7, were described by Antoine and Locht (24). Escherichia coil 
strain SM10 (25) was provided by S. Stibitz (Food and Drug Ad- 
ministration, Bethesda, MD). Broad-host-range plasmid pLAFRII 
(26) was provided by J. J. Mekalanos (Harvard University Medical 
Schod, Cambridge, MA). Phage cRIT20001 and phsmid pPTX42 
were described in Locht et al.  (11 and 27, respectively). Phage 
M13mp9 and plasmid pUC9 were purchased from Pharmacia LUB 
Biotechnology (Uppsala, Sweden). E. coli strains were grown in 
Luria-Bertani broth (28) supplemented with the appropriate anti- 
biotics. R pertuss/s strains were grown in flasks or in fermentors 
as described previously (24, 29). 
DNA Manipulations.  DNA manipulations were performed un- 
der standard conditions, as described by Maniatis et al. (28). DNA 
modifying enzymes were purchased from Boehringer Mannheim 
(Mannheim, Germany), Bethesda Research  Laboratories (Bethesda, 
MD), Pharmacia LKB (Uppsala, Sweden), or New England Bio- 
labs (Beverly,  MA) and were used according to the suppliers' recom- 
mendations. DNA sequencing was performed with Sequenase (US 
Biochemical  Corporation, Cleveland, OH) as recommended by the 
supplier. 
Mutagenesis oftheptx Operon.  AU mutations in theptx operon, 
except deletion of asparagine 105 of subunit $2, were performed 
with the Oligonucleotide-directed in vitro  Mutagenesis System 
(Amersham International,  Bucks, UK). To mutagenize  the $1 
subunit, we used phage cRIT20001 containing the coding region 
of the $1 subunit, and the oligonucleotides CCTCCGGCGGCA- 
GGGAGTCATA and TGCCAGATAGCCGCTCTGGTAG to re- 
place arginine 13 by a leudne residue (R13L) and glutamic acid 
129 by a glycine residue (E129G), respectively.  The mutations were 
subsequently introduced  in plasmid pRIT13070,  either by ex- 
changing  the  AccI fragment  (to  yield  pFTS1R13L) or  the 
SalI/Sau3AI fragment (to yield pPTS1E129G) with their respec- 
tive mutated sequences. 
To mutagenize the $2 cistron, the 750-bp XbaI/AvaI fragment 
of pPTX42 was inserted into M13mp19 digested with XbaI and 
XmaI to yield phage •RIT20200.  The deletion of the Tyr 102 codon 
was  performed  with  the  oligonucleotide  CGTTGCTGTAGT- 
GATCCGTT. The resulting phage, designated cRIT20201,  was 
then used to specifically  delete Tyr 103 in addition to Tyr 102 with 
the help  of the synthetic  oligonucleotide TGACGTTGCTGT- 
GATCCGTT. The resulting phage was named cRIT20202. The 
750-bp XbaI/SmaI fragment of pRIT13070 was then e~changed 
by the mutated XbaI/SmaI fragment from phages r  and 
soRIT20202 to yidd pFTAS2Y102 and pFrAS2Y102-103, respec- 
tively. To delete the Asn 105 codon from $2, the PCR technology 
was employed using the flanking oligonuchotides CGTTCTAGA- 
CCTGGCCCAGCCCCG  and  TGTCCCGC~GCGGTGGTT- 
CGAGTG, that contain, respectively, a XbaI and a SmaI site, and 
the mutagenic and partially complementary (over 14 bp) synthetic 
oligonueleotides TGC~GGTGACGCTGTAGTAG  and CAGCGT- 
CACCGCCACTCGCC'IGCrCTCCAG.  After in vitro amplifica- 
tion, the DNA fragment was digested with XmaI and XbaI and 
ligated into the same sites in pRIT13070. The recombinant mutant 
plasmid was named pPTAS2N105. 
To  perform  mutagenesis  of the  $3  cistron,  the  2510 bp 
XmaI/BamHI of pKIT13070  was first subcloned into pucg, 
thereby yielding pPT3. Then, a 960-bp PstI fragment from pPTX42 
carrying the coding region for the S3 subunit was subcloned into 
M13mp9 to yield phage cRIT20300.  To ddete Lys 10, Tyr 92, 
Lys 93, Tyz 102, Tyr 103, and Lys 105 of $3, the synthetic oligo- 
nucleotides  TGAACAGTGCCGC~GGGATG,  GCCCGGTCT- 
TTATGGTCGTG, GTTGCCCGGTGTATATGGTC, CCTTGC- 
TGTAGTGATCCGCA,  TGACCI'2~CIGTGATCCGCA,  and 
TGGCCGTGACGCTGTAGTAG were used,  respectively. After 
mutagenesis as described above, the 690-bp BglII/MluI fragment 
of pFT3 was exchanged with the corresponding mutated fragments 
from the M13mpg-derived phages. The mutated 1750-bp BgllI/ 
BamHI segment from the resulting recombinant phsmids were then 
exchanged with the BglII/BamHI region of pRIT13070. The final 
recombinant plasmids containing the desired mutations in the $3 
dstron of the PTX operon were named pFrAS3K10, pFFAS3Y92, 
pPTAS3K93, pFI"AS3Y102, pPTAS3Y102-103, and pPTAq3K105, 
respectively. 
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correct mutations had occurred and that no unwanted mutations 
were introduced into the exchanged fragments. 
To create pPT-RE, the two mutations in the $1 cistron were 
combined by exchanging the SalI/XbaI fragment of pFTS1RDL 
with the mutant SalI/XbaI region of pPTS1E129G. The ddetions 
of residue 105 in $2 and in 53 were combined to yield phsmid 
pPT-NK by replacing the 1591 bp MluI fragment ofpFTAS2N105 
with the mutagenized fragment from pP'rzkS3K105. Finally, pFT- 
RENK was constructed  by exchanging  the 887-bp KpnI/XbaI frag- 
ment of pPT-NK for the same fragment from pPToRE. 
Expression of the Mutated ptx Genes in R  t,  ertussis.  The 4.7-kb 
EcoRI fragments of the pRIT13070-derived plasmids containing 
the described  mutations in the $2 or $3 cistrons were inserted into 
the EcoRI site of the broad host range plasmid pLAFRII. The 
recombinant phsmids were introduced into R pertuss/s strain BPRA 
by conjugation as described  before (24) using E. coli SM10 as a donor 
strain. Recombinant R pertuss/s were grown in modified Stainer 
Schoke medium (30) containing cyclodextrin  (24) and tetracycline. 
After growth, the cells were separated from the culture medium 
by centrifugation and the supernatant was used directly in ELISA 
and CHO cell clustering assays. 
Alternatively, plasmids pPT-RE, pPT-NK, or pFT-RENK were 
introduced into R  pertussis strain BPRA by electroporation (31). 
The transformed cells were plated on Bordet-Gengou medium con- 
taining ampicillin (24). As these pUC-derived plasmids are unable 
to replicate in R permss/s, the resulting colonies were expected to 
contain a copy of the plasmids integrated into the chromosome 
via a single recombination event. The recombinant strains were 
named respectively  BPRA/RE, BPRA/NK, and BPRA/RENK. 
After growth of these strains in a 10-liter fermentor, FIX or the 
PTX-CRMs were adsorbed on hydroxylapatite  (HA-ultrogel) and, 
upon elution, further purified by hydrophobic interaction chroma- 
tography (Butyl TSK), dye-ligand  chromatography  (Trisacryl  blue), 
and gel filtration (Sephacryl S-200 HR) (29). 
Iramunoprecipitation.  PTX (500 ng) were incubated for 2 h at 
room temperature with 5/~g of various mAbs in 250/~1 PBS con- 
taining 0.1% Tween  20. 50 #1 of  suspension of  Immunobeads  rabbit 
anti-mouse Ig (H +  L) (Bio-Rad Laboratories, Richmond, CA) 
were added and the mixture was incubated overnight at 4~  The 
beads were then collected  by centrifugation, resuspended  in loading 
buffer, and submitted to SDS-PAGE (32). Upon separation, the 
proteins were transferred onto nitrocellulose membranes, and the 
FTX subunits were detected with mAbs (21) or by a mixture of 
biotinylated rabbit and goat anti-PTX polyclonal  antibodies. These 
polyclonal  antibodies were obtained from animals  hypetimmunized 
with formaldehyde-detoxified  FIX. 
Analytical  Procedures.  ELISA  using polyclonal antibodies or 
mAbs and haptoglobin-binding assays  were carried out as described 
before (24). CHO cell cytotoxidty of FIX, FIX-CRMs, or the 
various R pertussis culture supernatants was estimated as described 
by Hewlett et al. 03). To measure the inhibition of CHO cell ac- 
tivity of PTX by mAbs, serial dilutions of ascitic fluids containing 
the antibodies were added to 1.5/~g of FIX. The mixture was 
incubated for 3 h at 37~  before addition to the CHO ceils. A 
mAb is considered  neutralizing when the corresponding  ascitic  fluid 
is able to inhibit the CHO cell-clustering  activity of  PTX at a dilu- 
tion equal or superior to 160. 
Nicotinamide adenine  dinucleotide  (NAD)-glycohydrolase  assays 
were performed as described by Locht et al. (34). The inhibition 
of the NAD-glyeohydrohse  activity  by mAbs vo.s  evaluated  by prein- 
cubating the 0.2/~g of the $1 subuuit to be introduced in the test 
with 1/~g of purified antibody for 30 rain at room temperature. 
In the inhibition assay, we used a recombinant $1 subunit carrying 
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the mutation Cys41--~Ser (35). Using this molecule, the NAD- 
glycohydrolase  assay  is performed in the absence of  reducing agent. 
A mAb is considered neutralizing when 1/~g of purified antibody 
is able to reduce the NAD glycohydrolase  activity of 0.2/~g of 
$1 subunit by at least a fourfold factor. 
1I.,2 Secretion.  Freshly  prepared spleen cells from BALB/c  mice 
were suspended at  a final density of 104 cells/ml in complete 
medium (RPM11640 medium supplemented  with 1% normal mice 
serum, 1% L-glutamin (043-05030H), 1% penicillin-streptomycin 
(043-0DSOD), and 1% B-ME (043-05140H) all from Gibco Labora- 
tories (Grand Island, NY). 100/A of this suspension  was distributed 
in each well of a 96-well plate. To these wells, 100 #1 of FTX solu- 
tions at various concentrations were added, and the plates were 
incubated for 24 h at 37~  100/A of supernatant were then har- 
vested, transferred to new microtiter plates, and frozen for at least 
24 h to kill surviving cells. The concentration of IL-2 present in 
these supernatants was evaluated  by adding to each well 104 freshly 
washed VDA2 cells suspended  in 100 #1 of  complete medium con- 
taining 1% pyruvate, 1% nonessential amino acids, and 10% FCS. 
After a 24-h incubation, 1 #Ci [3H]thymidine (TRA120; Amer- 
sham Corp.) was added. 16-18 h later, the cells were harvested and 
the amount of internalized radioactivity was determined by liquid 
scintillation. The stimulation index was calculated as the ratio of 
the radioactivity incorporated in the presence of  toxin to the radio- 
activity incorporated in the absence of toxin. 
lraraunogenicity.  Groups  of 10 mice (OF1; IFFA  Credo, Lyon, 
France) were immunized subcutaneously  with 1/~g of  PTX-CRM 
adsorbed on aluminium hydroxide. 3 wk hter, the animals were 
bled and given a second dose of 1/~g of FTX-CRM as previously. 
1 wk after the booster dose, total bleeding was performed and in- 
dividual sera were tested by ELISA to determine the titer of an- 
titoxin antibodies. Titers were expressed in arbitrary ELLS?,  units 
by comparison with a mouse reference serum. Pooled sera were 
used to evaluate the CHO neutralizing antibody titers. 
Results 
Rationale for the Design of  B Oligoraer Mutations.  Nogimori 
et al. (36) have previously shown that chemical modification 
of lysine residues abolishes  several but not all biological ac- 
tivities  of PTX.  The  activities  that  are  affected  by  the 
modification oflysines are those that involve dimer 2. There- 
fore, lysine residues  in the $3 subunit not conserved in $2 
may be located at its receptor-binding site. Three noncon- 
served lysine residues  can be found in the sequence  of the 
$3 subunit: Lys 10, Lys 93,  and Lys 105 (22,  23).  They are 
replaced by glutamine, asparagine, and asparagine, respectively, 
in the $2 subunit. It is therefore possible that one or several 
of these three lysine residues are involved in D2-specific binding 
of PTX. 
Iodination of PTX severely reduces biological activities, 
such as hemagglutination and CHO cell cytotoxicity. Fetuin 
coupled to agarose can prevent inactivation of the toxin by 
iodination  (37).  Since  iodination usually affects  tyrosine 
residues, it is possible that tyrosine residues, conserved in $2 
and $3, are close to their receptor-binding sites. Of the many 
tyrosines in $2 and $3,  all but two in $3 are at conserved 
positions. Two of them (Tyr 102, and Tyr 103) are in dose 
proximity to Lys 105 in $3, and one of them (Tyr 92) is close 
to Lys 93 in $3. This led us to examine the importance of 
Tyr 102, Tyr 103,  and Ash 105 in $2, and Lys 10, Lys 93, 
Tyr 102, Tyr 103, and Lys 105 in $3 in B oligomer activities. Table  1.  Haptoglobin-binding of Culture Supernatants of 
B. pertussis Strains Producing PTX or PTX-CRM 
Haptoglobin-binding 
(percent residual binding)* 
WT*  100 
S2:Y102A  50 
S2:Y102/103AA  4 
S2:N105A  <1 
S3:Y102A  144 
S3:K105A  102 
* Calculated as 100 x (concentration  of PTX evaluated  in dimer  1-specific 
ELISA/total concentration  of PTX). 
*  R/x*auss/s strain BPR.A containing  pLAFKII with either  the wild-type 
ptx gene  (WT) or mutant  ptx genes  resulting  in the indicated  alterations 
of the $2 or $3 subunit. 
Activities of the PTX-CRM.  To identify PTX-CRM which 
possess altered haptoglobin-binding activities, Tyr 102, Tyr 
103, or Asn 105 in the $2 subunit were deleted by site-directed 
mutagenesis of the $2 gene, and each of the three mutant 
genes (Y102A, Y102A/Y103A, and N105A) was introduced 
into BPRA on a pLAFRII-derived plasmid.  The resultant 
recombinant BPRA strains were then analyzed for the ex- 
pression of the mutant ptx genes by ELISA using culture su- 
pernatants. All strains produced and secreted PTX-CRM, in- 
dicating that none of the mutations abolished expression, 
assembly, or secretion (data not shown). When haptoglobin 
was used in the model ELISA for dimer 1-specific binding, 
drastic differences  in the haptoglobin-binding were observed 
among the different PTX-CRM analyzed (Table 1). Dele- 
tion of Tyr 102 only reduced haptoglobin-binding by about 
50%. Deletion of  both Tyr 102 and Tyr 103 reduced binding 
to 4% of residual activity. Ddetion of Asn 105 resulted in 
Table  2.  CHO-Cell-dustering Activity of Culture Supernatants 
of B. pertucsis Strains Producing PTX or PTX-CRM 
CHO ceil clustering 
activity (dil)* 
WTt  64 
S3:K10A  2 
S3:Y92A  16 
S3:K93A  4 
S3:Y102A  64 
S3:Y102/103AA  4 
S3:K105A  <2 
* Expressed as the reciprocal  of the highest dilution at which  clustering 
is observed. 
t B. perm~ strain BPRA containing  pLAFRII with either  the wild-ty~ 
p~ gene  (WT) or mutant  Fix genes  resulting  in the indicated  alterations 
of the $2 or $3 subunit. 
no detectable haptoglobin-binding,  and therefore to <1% re- 
sidual activity. No effect on the haptoglobin-binding capacity 
was observed when Glu 129 of the $I subunit was modified 
(not shown). In addition, the deletion of Tyr 102 or Lys 105 
in the $3 subunit also had no effect on haptoglobin-binding. 
Therefore, heptoglobin-binding specifically  involves the Asn 
105 residue of the $2 subunit. 
Since D2 was reported to specifically bind to CHO cell 
membrane receptors (18), several  site-directed mutations were 
introduced in the $3 subunit gene and the resulting mutant 
proteins  analyzed for their residual CHO cell cytotoxicity. 
As shown in Table 2, deletion of neither Tyr 92 nor of Tyr 
102 had any significant effect on the CHO cell cytotoxicity. 
In contrast,  CHO cell cytotoxicity was greatly reduced but 
detectable in PTX-CRM carrying the deletion of Lys 10, Lys 
93 and the double deletion of Tyr 102 and Tyr 103 in the 
S3 subunit.  No cytotoxicity was observed with PTX-CRM 
in which Lys 105 of $3 was deleted. ELISA  using mAbs against 
individual subunits indicated that none of the described mu- 
tations affected the stoichinmetry  of the individual subunits, 
suggesting the structural integrity of correctly assembled  PTX- 
CRM (data not shown). 
These results indicate that asparagine 105 of subunit $2 
and the lysine residues 10, 93, and especially 105 in $3 are 
involved in the biological activities of  FIX, probably through 
their specific interactions with the toxin receptor. We chose 
the deletion of the two residues at position  105 for further 
analysis. 
Construction of R  pertussis Strains BPRA-NK, BPRA.RE, 
and BPRA.RENK.  To further investigate the effect of the 
deletion of  residues 105 in $2 and $3 on the activities of  FrX, 
both mutations were combined in the same pt~ gene and in- 
troduced into the t~ permss/s BPRA chromosome  by homol- 
ogous recombination. Both mutations were introduced into 
pRIT13070  to yield pPT-NK as described in Materials and 
Methods. This plasmid was then introduced into the PTX- 
deficient R permss/s BPRA strain by electroporation. Integra- 
tion of pPT-NK into the/~ pea~s/s BPRA chromosome was 
obtained by homologous recombination involving the flanking 
regions of the ptx gene. In a similar way, PTX-CRM were 
constructed containing alterations in the $1 subunit to com- 
pare them with the B oligomer mutants with respect to the 
various biological activities. Substitutions of  both Arg 13 and 
Glu 129 by, respectively, Leu and Gly were chosen because 
these changes affect either NAD binding or catalysis (9, 11, 
and Antoine, R., A. Tallett, S. van Heyningen, and C. Locht, 
manuscript in preparation). A combination of two mutations 
affecting the enzymatic activity of PTX results generally in 
undetectable levels of biological activities that are dependent 
of ADP-ribosyltransferase activity of the toxin (12-14). The 
R permss/s strain containing these $1 mutations was named 
BPRA-RE. Hnally, we combined all four mutations (muta- 
tions R13L and E129G in $1, deletions N105A and K105A 
in  $2  and  $3,  respectively)  in  a  single  strain  named 
BPRA-RENK. 
Western blot and ELISA analyses on the culture superna- 
tants indicated that the resulting strains were able to produce 
and secrete  FrX-CRM, reactive  with anti-FrX mAbs specific 
82  Mutations  in the B Oligomer  of Pertussis Toxin Table  3.  Immunoprecipitation  of PTX and PTX-RENK with 
Anti-PTX mAbs 
Immunoprecipation 
Antibody 
(ELISA reactivity)  PTX  Irr-RENK 
5C2  (S1)*  + *~  + 
64A3  (S1)*  +  + 
85B4  (Sl)**  +  + 
F18C6  (D2)S  ND  + 
27F9  (D1/D2)II  +  + 
86E1  (D1/D2)  +  + 
F6D1  (D1)I  ND  + 
59F4  (D2)**  ND  + 
* Recognizes S1 in Western blot. 
Neutralizes CHO cell clustering and NAD glycohydrolase  activities of 
PTX. 
$ Recognizes $3 in Western blot; neutralizes the CHO cell-clustering 
activity of PTX; and reduces the haptoglobin binding of PTX. 
II Recognizes $4 weakly in Western blot. 
ql Neutralizes both the CHO cell-clustering activity and the haptoglobin 
binding of PTX. 
** Neutralizes the CHO cell-clustering activity of PTX. 
** Upon immunopreeipitation, all PTX subunits are detected on Western 
blot. 
for S1 or the B oligomer (not shown). To verify its correct 
assembly, we immunoprecipitated PTX-RENK in parallel with 
wild-type PTX using mAbs recognizing the different subunits 
(Table 3). The results showed that all of the tested antibodies, 
directed either against $1 or the B oligomer, and able to in- 
hibit  the activities of PTX,  such as NAD  glycobydrolase, 
CHO cell cytotoxicity, and haptoglobin binding, were also 
able to recognize and precipitate both holotoxins. Taken to- 
gether, these results indicated that the mutations in $1, $2, 
and $3 and their combination do not abolish production, as- 
sembly, and secretion of the PTX-CRM. The R/mmss/s strains 
BPRA-RE, BPRA-NK, and BPRA-REIqK were subsequently 
grown  in  fermentors  and  the  PTX-CRM  produced  and 
secreted by these strains were purified near homogeneity. 
Table  4.  NAD GlycohFlrolase  and ClIO Cell-Clustering  Activities 
of Purified PTX and PTX-CRM 
NAD glycohydrolase 
(pmole rain -* tzg 
PT- *) 
CHO Cell Clustering 
(percent  residual 
toxicity) * 
PTX  0.36  100 
PTX-RE  <0.03  <0.0013 
PTX-NK  0.26  7.5 
PTX-RENK  ND  <0.0020 
* Expressed as 100 x (highest dilution of tested PTX hxducing no cluster- 
ing/highest dilution of wild-type PTX inducing no dusteting). 
Activities of the Purified PTX-CRM.  The enzymatic ac- 
tivities of the purified FTX-CRM were analyzed and com- 
pared with those of the wild-type holotoxin.  As shown in 
Table 4,  PTX-NK expressed NAD glycohydrolase activity 
at a level similar to purified PTX, whereas no significant ac- 
tivity was expressed by PTX-RE up to a concentration  of 
20/zg/ml,  representing  a reduction  in  activity of at  least 
10,000-fold. These results are consistent with the effect of 
the S1 alterations in isolated $1 analogs produced in E. coli 
(8-11) and confirm that the mutations in the B oligomer do 
not  affect the enzymatic  activities of S1. 
The CHO cell-clustering assays showed that all three mu- 
tant holotoxins expressed diminished cytotoxic activity. As 
expected and consistent with previous results (12-14), no cyto- 
toxic activity could be measured with PTX-RE and PTX- 
RENK, because of the effect of the S1 mutations on the en- 
zymatic activities. PTX-NK showed low but detectable (7.5% 
of wild-type level)  CHO cell-dustering  activity (Table 4). 
The decrease of cytotoxicity observed with PTX-NK was in- 
dependent of the enzymatic activity, supporting the impli- 
cation of the B oligomer mutations in the receptor-binding 
activity of the toxin as the cause of the diminished toxicity. 
To investigate whether the alterations in the B oligomer 
also affect the mitogenic activity of PTX for T cells, we com- 
pared the effect of the mutant holotoxins and of the wild- 
type PTX on spleen cells  from naive mice.  To specifically 
evaluate the effect on T cells, we measured the Ib2 secretion 
in the culture supernatant instead of proliferation. As shown 
in Fig. 1, no I1.,2 secretion was detected for PTX-RENK and 
PTX-NK at all concentrations tested, whereas 1-3/zg/ml of 
PTX or PTX-RE clearly induced II~2 secretion. This showed 
that the reduction of the binding properties of PTX-CRM 
also affects the induction of IL-2 secretion, and consequently 
its mitogenicity for T  cells. 
Immunogenicity of  PT-RE and PT--RENK.  It was interesting 
to investigate whether the reduction of the B oligomer-specific 
activities also reduces the immunogenicity of PTX-RENK. 
We therefore compared its immunogenicity to that of PTX-RE 
25 
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Figure 1.  IL-2  secretion  by mice spleen  cells  induced by various concen- 
trations of PTX analogs. BALB/c  spleen cells were incubated with indi- 
cated concentrations of various PTX-CRM for 24 h at 370C. The IL-2 
concentration in the culture supernatant was measured in a proliferation 
assay using VDA2 cells. The results are expressed as stimulation index 
(SI). (Dotted line) SI value of 1. 
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Figure 2.  Immunogenicity of PTX-R.E and PTX-RENK. Groups  of 
10 mice were immunized twice subcutaneously with 1/~g of FI'X-CRM 
with a 3-wk interval.  $era were taken at the time of the injection of the 
second dose ([~)  and 1 wk later  (~).  (A) Total anti-PTX response ex- 
pressed as the geometric mean titer of the individual  sera. (B) CHO cell 
assay neutralization  titers are shown as reciprocal of the highest dilution 
resulting  in 100% inhibition in a CHO cell-clustering  assay. 
in outbred mice (Fig. 2). We did not include I~X-NK in 
this comparison because  of its too high residual  toxicity. 
1 wk after the second immunization, no significant  differ- 
ence in the production of neutralizing antibodies could be 
observed between the two groups, and only slight differences 
were detected for total anti-PTX antibody titers, indicating 
that the B oligomer mutations do not significantly affect the 
immunogenicity of PTX-RENK. 
Discussion 
Specific binding to its receptors represents the initial step 
in the pathophysiologic action of a bacterial toxin. PTX, one 
of the most complex bacterial  toxins known to date,  con- 
tains several receptor-binding sites. Although the receptors 
for PTX have not yet been identified, several glycoproteins 
on cell surfaces and host tissues, as well as some serum glyco- 
proteins, such as haptoglobin and fetuin, have been demon- 
strated to bind to PTX. The carbohydrate portion of these 
proteins appears to be essential for their interaction with PTX. 
Some of these glycoproteins are known to contain terminal 
sialyllactosamines  which are important for toxin binding, since 
their removal abolishes binding to the toxin (17, 38).  The 
nature of both the polypeptide and carbohydrate portions may 
vary among the various PTX-receptors, and this variation is 
responsible for the dimer 1- or dimer 2-specific binding of 
PTX (18). In this study, we show that Asn 105 of the $2 
subunit is important for binding of the toxin to sialogly- 
coproteins such as haptoglobin, whereas the analogous Lys 
105 of the S3 subunit is involved in the interaction with CHO 
cells. These results are in good agreement with previous ob- 
servations showing that dimer 1 ($2-$4) preferably binds to 
haptoglobin (20, 21), and dimer 2 ($3-$4) to the CHO cell 
membrane receptor (18). Together, these observations  sug- 
gest that haptoglobin-binding involves $2,  and CHO cell 
receptor binding involves $3, and that Asn 105 and Lys 105, 
respectively, are important residues in these specific  interactions. 
Given the importance of the negatively charged sialic acid 
residues in PTX binding, it is tempting to speculate that the 
positively charged Lys 105 of $3, and the strongly polar Asn 
105 of $2 may interact with the terminal sialyl groups on 
the receptor molecules.  Consistent with this hypothesis is 
that sialyllactose markedly inhibits dimer 2 binding, but has 
less effect on dimer I binding (18), the electrostatic interac- 
tions being weaker. While this paper was in preparation, Sank- 
konen et  al.  (39)  identified carbohydrate  recognition do- 
mains on the $2 and $3 subunits produced in E.  coli at the 
NH2-terminal  half of  the  subunits,  some  of which  are 
reasonably close to residues 105 in the primary sequence. The 
amino acid residues interacting with the sugar moieties would 
be expected to lie in close proximity to those interacting with 
the sialyl groups. It is interesting that alterations  of Lys 10 
or Lys 93 of the $3 subunit, both located in the carbohydrate 
recognition domains proposed by Saukkonen et al. (39) also 
resulted in a decrease of CHO cell cytotoxicity, albeit to a 
lesser extent than the alteration of Lys 105 (Table 2). 
Antibodies directed against various $2- or S3-specific pep- 
tides showed that those reacting with peptides corresponding 
to the regions located in the vicinity of residue 105 have the 
highest toxin-neutralizing activities, presumably because of 
their interaction with receptor binding (40). On the other 
hand, most toxin-neutralizing mAbs reactive  with the B 
oligomer, including those presented in this study, appear to 
recognize conformational epitopes (41, 42), suggesting that 
the receptor-binding of PTX depends on the conformation 
of the B oligomer. The FFX-CRM presented in this study 
reacted with a panel of mAbs, most of which recognize con- 
formational epitopes,  including the neutralizing antibodies 
reactive with the B oligomer. As determined by immuno- 
precipitation, the antigenicity of I~X-RENK was indistin- 
guishable from that of PTX-RE, indicating that the altera- 
tions in the B oligomer did not affect the conformation in 
an important way. This observation also suggests that the 
residues 105 may not be exposed at the surface of the toxin, 
but rather lie within a canyon or a pocket in the $2 and $3 
subunits, similar to what has been proposed for the receptor- 
binding sites of many viruses (43). 
Although many biological activities  of PTX depend on 
its Sl-catalyzed  ADP-ribosyltransferase  activity,  some, such 
as mitogenicity, are independent of this enzymatic activity 
(15). In fact, reduction in enzymatic activity may sometimes 
result in increased mitogenic activity (16). The PTX-CRM 
with impaired receptor-binding abilities, however, presents 
an undetectable level of T cell mitogenicity, as indicated by 
its inability to stimulate II~2 secretion by spleen cells exposed 
to the holotoxin, regardless of the toxin's ability to catalyze 
ADP-ribosylation.  This  demonstrates  that  reduction  in 
receptor-binding not only reduces the ADP-ribosyltransferase- 
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biological activities of PTX. It is interesting that toxin mol- 
ecuhs used in current acdluhr vaccine formulations are often 
inactivated by treatments with formaldehyde or glutaralde- 
hyde (4, 44), chemicals that primarily affect lysine residues 
in proteins.  Since the $1  subunit does not contain  lysines, 
the chemical treatment is likely to affect the B oligomer-specific 
activities. 
In vivo, FiX-stimulated II,2 secretion may have adjuvant 
effects (45). As shown in Fig. 2, immunogenicity of trrx - 
RENK was slightly lower than  that  of FIX-RE with re- 
spect to the production of total anti-PTX antibodies, but no 
difference was observed between the two PTX-CRM when 
toxin-neutralizing antibodies were compared. This shows that 
if the B oligomer alterations affecting I1,2-secretion induced 
slightly decreased total anti-FiX  antibodies,  they did not 
significantly affect the production of physiologically impor- 
tant  anti-FiX  antibodies in the mouse. 
The identification and subsequent alteration  of the receptor- 
binding sites on toxins is expected to help in the design of 
genetically detoxified molecules devoid of any detectable ac- 
tivity but structurally nearly identical to the original mole- 
cule. This approach is particularly useful for the development 
of new generation vaccines against infectious diseases medi- 
ated by bacterial toxins. Pertussis or whooping cough is such 
a toxin-mediated disease against which a new generation vac- 
cine  is  highly  desirable.  A  recent  important  clinical  trial 
confirmed that FIX, either alone or in conjunction with other 
R  pertussis  antigens,  was highly protective in children,  and 
should therefore be included in the new vaccines against per- 
tussis (5). However, complete detoxification of this molecule 
would be an absolute prerequisite before a PTX-based vac- 
cine can be routinely used. The genetic modifications of the 
trI'X gene presented in this study clearly demonstrate that 
alterations  of the receptor-binding  sites  strongly affect the 
biological activities of PTX. The reported alterations not only 
affected the activities that are dependent on the $1 subunit- 
catalyzed ADP-ribosylation, but also those that are indepen- 
dent of this enzymatic activity, in particular, the FIX-mediated 
mitogenidty. Despite the reduction of both ADP-ribosyltrans- 
ferase-dependem and -independent activities, the FIX-KENK 
was able to elicit high titers of toxin-neutralizing antibodies, 
and therefore a PTX-CKM with alterations in the $1 subunit 
as well as in the B oligomer, such as the one described here, 
may be considered a useful candidate for the development 
of a new generation  vaccine against  whooping cough. 
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